June 16, 2020 07:22 AM EDTUpdated 11:33 AM

Covid-19 roundup: An old, cheap steroid proves to be a major boon to coronavirus patients; BARDA puts $85M behind Regeneron antibody effort

Amber Tong

Senior Editor

Jason Mast

Editor

John Carroll

Editor & Founder

Researchers today spotlighted data from a clinical study offering the first hard evidence that a treatment can save the lives of patients suffering from Covid …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Covid-19 roundup: An old, cheap steroid proves to be a major boon to coronavirus patients; BARDA puts $85M behind Regeneron antibody effort

Amber Tong

Senior Editor

Jason Mast

Editor

John Carroll

Editor & Founder

Sign up to read this article for free.

Among pharma CEOs, the IRA now and the IRA later get very different reactions

Bristol Myers restarts radiopharmaceutical Phase 3 trial, but delays readout by one year

Updated: With cost-cutting underway, Bristol Myers raises guidance, touts Phase 3 win and scraps another

Andrew Left, short seller who campaigned against Valeant, is accused of fraud by SEC

European drug regulator rejects Alzheimer's drug Leqembi, citing safety concerns

Critical Junctures in Gene Therapy Clinical Material Manufacturing: Where Do I Start? And Will It Work?

Covid-19 roundup: An old, cheap steroid proves to be a ma­jor boon to coro­n­avirus pa­tients; BAR­DA puts $85M be­hind Re­gen­eron an­ti­body ef­fort

Senior Editor

Editor

Editor & Founder

Sign up to read this article for free.

Covid-19 roundup: An old, cheap steroid proves to be a major boon to coronavirus patients; BARDA puts $85M behind Regeneron antibody effort